Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Joint Infection: early-phase trial registry

3 of 7 indexed Joint Infection trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Joint Infection: 7 US clinical trials tracked, 3 recruiting.

Joint Infection is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Infectious Diseases Physicians, running 1 of these trials.

Enrollment posture brief

Registry condition joint-infection

OPEN 3 | RECR 43% | LATE 1 | EARLY 2 | RANK #2497 | SPON 1

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Joint Infection (this)43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Joint Infection

Joint Infection lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Joint Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Joint Infection is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Joint Infection trials is spread across many organizations.

    Infectious Diseases Physicians accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Joint Infection enrolment sits around 180 participants.

    Median target enrolment is 180 among the 7 trials that report a genuine target (sentinel values excluded). 2 of those (28.6%) plan for fewer than 100 participants.

  4. Joint Infection research is mostly interventional.

    6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 41

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 4 1

Named interventions

Most-linked intervention names on Joint Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Omadacycline Pill Drug
1 trials
PLG0206 Drug
1 trials
Saline irrigation Other
1 trials
No-Rinse Solution (NS) Other
1 trials
Synovial Staphylococcus spp antigen panel Diagnostic test
1 trials
Synovial C-reactive Protein (CRP) Diagnostic test
1 trials
Synovial lactate assay Diagnostic test
1 trials
Synovial Neutrophil elastase assay Diagnostic test
1 trials

US sites by state

Facility locations filed on Joint Infection trials. A trial with sites in several states counts in each.

New York 3 trials
California 3 trials
West Virginia 1 trials
Virginia 1 trials
Utah 1 trials
Texas 1 trials
Tennessee 1 trials
Pennsylvania 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Joint Infection page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Joint Infection condition card totals 7 registered trials; most-linked intervention Omadacycline Pill; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.